Contineum Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Contineum Therapeutics, Inc. (CTNM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 84.4% of the shares are freely tradable; institutional investors hold 94.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 7.55 | 2,841,334 | +0.0 | 03/31/2026 |
| HHG PLC | 7.27 | 2,734,836 | +11.7 | 03/31/2026 |
| Johnson & Johnson | 5.26 | 1,979,173 | +0.0 | 06/30/2026 |
| Franklin Templeton Inc | 4.89 | 1,839,227 | -2.1 | 03/31/2026 |
| Balyasny Asset Management LLC | 4.48 | 1,685,635 | -8.5 | 03/31/2026 |
| Baker Bros Advisors LP | 3.78 | 1,420,838 | +0.0 | 03/31/2026 |
| RA Capital Management, LLC | 3.44 | 1,296,012 | -40.5 | 03/31/2026 |
| Perceptive Advisors LLC | 3.34 | 1,255,592 | +0.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 3.23 | 1,214,173 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 3.09 | 1,163,007 | +0.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President | 17,217 | 232,430 $ | Sep 8, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Stengone Carmine N. | CEO and President | Sell | 2,500 | 16.46 | 41,142 |
| Sep 8, 2026 | Stengone Carmine N. | CEO and President | Other | 2,500 | 1.01 | 2,525 |
| Aug 3, 2026 | Stengone Carmine N. | CEO and President | Sell | 2,500 | 16.01 | 40,029 |
| Aug 3, 2026 | Stengone Carmine N. | CEO and President | Other | 2,500 | 1.01 | 2,525 |
| Jul 8, 2026 | Stengone Carmine N. | CEO and President | Sell | 2,500 | 16.00 | 40,000 |
| Jul 8, 2026 | Stengone Carmine N. | CEO and President | Other | 2,500 | 1.01 | 2,525 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.